Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU
BaŞaran et al., Turk. J. Med. Sci., doi:10.3906/sag-2006-173
BaŞaran et al., Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the.., Turk. J. Med. Sci., doi:10.3906/sag-2006-173
Jul 2020   Source   PDF  
  All Studies   Meta
Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ, 113 with HCQ+AZ, and 32 with regimens including favipiravir. 75% reduction in the median time to clinical improvement for HCQ+AZ vs. FAV, RR 0.25, p<0.001. 83% reduction for HCQ. However, there was significant confounding by indication.
There were no significant adverse events.
BaŞaran et al., 28 Jul 2020, prospective, Turkey, peer-reviewed, 18 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Turkish Journal of Medical Sciences Research Article Turk J Med Sci (2021) 51: 411-420 © TÜBİTAK doi:10.3906/sag-2006-173 Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU 1, 1 2 Nursel ÇALIK BAŞARAN *, Oğuz Abdullah UYAROĞLU , Gülçin TELLİ DİZMAN , 1 3 2 2 4 Lale ÖZIŞIK , Taha Koray ŞAHİN , Zahit TAŞ , Ahmet Çağkan İNKAYA , Sevilay KARAHAN , 2 5 2 2 1 Şehnaz ALP , Alpaslan ALP , Gökhan METAN , Pınar ZARAKOLU , Gülay SAİN GÜVEN , 1 6 2 2 2 Şerife Gül ÖZ , Arzu TOPELİ , Ömrüm UZUN , Murat AKOVA , Serhat ÜNAL  1 Department of Internal Medicine, General Internal Medicine Division, Faculty of Medicine, Hacettepe University, Ankara, Turkey 2 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey 3 Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey 4 Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 5 Department of Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey 6 Department of Internal Medicine, Intensive Care Division, Faculty of Medicine, ,Hacettepe University, Ankara, Turkey Received: 16.06.2020 Accepted/Published Online: 26.07.2021 Final Version: 30.04.2021 Background/aim: Despite the fact that the COVID-19 pandemic has been going on for over 5 months, there is yet to be a standard management policy for all patients including those with mild-to-moderate cases. We evaluated the role of early hospitalization in combination with early antiviral therapy with COVID-19 patients in a tertiary care university hospital. Materials and methods: This was a prospective, observational, single-center study on probable/confirmed COVID-19 patients hospitalized in a tertiary care hospital on COVID-19 wards between March 20 and April 30, 2020. The demographic, laboratory, and clinical data were collected. Results: We included 174 consecutive probable/confirmed COVID-19 adult patients hospitalized in the Internal Medicine wards of the University Adult Hospital between March 20 and April 30, 2020. The median age was 45.5 (19–92) years and 91 patients (52.3%) were male. One hundred and twenty (69%) were confirmed microbiologically, 41 (23.5%) were radiologically diagnosed, and 13 (7.5%) were clinically suspected (negative microbiological and radiological findings compatible with COVID-19); 35 (20.1%) had mild, 107 (61.5%) moderate disease, and 32 (18.4%) had severe pneumonia. Out of 171 cases, 130 (74.3%) showed pneumonia; 80 were typical, and 50 showed indeterminate infiltration for COVID-19. Patients were admitted within a median of 3 days (0-14 days) after symptoms appear. The median duration of hospitalization was 4 days (0-28 days). In this case series, 13.2% patients were treated with hydroxychloroquine alone, 64.9% with hydroxychloroquine plus azithromycin, and 18.4% with regimens including favipiravir. A total of 15 patients (8.5%) were transferred to the ICU. Four patients died (2.2%). Conclusion: In our series, 174 patients were admitted to the hospital wards for COVID-19, 69% were confirmed with PCR and/or antibody test. At the time of admission, nearly one fifth of the patients had severe diseases. Of the patients, 95.4% received hydroxychloroquine alone or in combination. The overall case fatality rate was 2.2%. Key words: COVID-19, noncritical illness,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop